Integrated NY-ESO-1 antibody and CD8(+) T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

Ipilimumab, a monoclonal antibody against cytotoxic T lymphocyte antigen 4 (CTLA-4), has been shown to improve survival in patients with advanced metastatic melanoma. It also enhances immunity to NY-ESO-1, a cancer/testis antigen expressed in a subset of patients with melanoma. To characterize the a...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Yuan, Jianda, Adamow, Matthew, Ginsberg, Brian A., Rasalan, Teresa S., Ritter, Erika, Gallardo, Humilidad F., Xu, Yinyan, Pogoriler, Evelina, Terzulli, Stephanie L., Kuk, Deborah, Panageas, Katherine S., Ritter, Gerd, Sznol, Mario, Halaban, Ruth, Jungbluth, Achim A., Allison, James P., Old, Lloyd J., Wolchok, Jedd D., Gnjatic, Sacha
Natura: Artigo
Lingua:Inglês
Pubblicazione: National Academy of Sciences 2011
Soggetti:
Biological Sciences
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3189057/
https://ncbi.nlm.nih.gov/pubmed/21933959
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1110814108
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi